{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:27:41Z","timestamp":1792985261470,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-0035"],"award-info":[{"award-number":["ANR-10-LABX-0035"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Charcot-Marie-Tooth disease type 1 A (CMT1A) lacks an effective treatment. We provide a therapy for CMT1A, based on siRNA conjugated to squalene nanoparticles (siRNA PMP22-SQ NPs). Their administration resulted in normalization of Pmp22 protein levels, restored locomotor activity and electrophysiological parameters in two transgenic CMT1A mouse models with different severity of the disease. Pathological studies demonstrated the regeneration of myelinated axons and myelin compaction, one major step in restoring function of myelin sheaths. The normalization of sciatic nerve Krox20, Sox10 and neurofilament levels reflected the regeneration of both myelin and axons. Importantly, the positive effects of siRNA PMP22-SQ NPs lasted for three weeks, and their renewed administration resulted in full functional recovery. Beyond CMT1A, our findings can be considered as a potent therapeutic strategy for inherited peripheral neuropathies. They provide the proof of concept for a new precision medicine based on the normalization of disease gene expression by siRNA.<\/jats:p>","DOI":"10.1038\/s42003-021-01839-2","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T06:03:14Z","timestamp":1615269794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7639-2256","authenticated-orcid":false,"given":"Suzan","family":"Boutary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1588-1501","authenticated-orcid":false,"given":"Marie","family":"Caillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9vidette","family":"El Madani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Vallat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9934-7199","authenticated-orcid":false,"given":"Julien","family":"Loisel-Duwattez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Rouyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Urbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Desma\u00eble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1012-9783","authenticated-orcid":false,"given":"Andoni","family":"Echaniz-Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-4108","authenticated-orcid":false,"given":"David","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Couvreur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Massaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9636-4559","authenticated-orcid":false,"given":"Liliane","family":"Massaad-Massade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"1839_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.bbadis.2014.07.031","volume":"1852","author":"NU Jerath","year":"2015","unstructured":"Jerath, N. U. & Shy, M. E. Hereditary motor and sensory neuropathies: understanding molecular pathogenesis could lead to future treatment strategies. Biochim. Biophys. Acta 1852, 667\u2013678 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"1839_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mgg3.390","volume":"6","author":"AN Cutrupi","year":"2018","unstructured":"Cutrupi, A. N., Brewer, M. H., Nicholson, G. A. & Kennerson, M. L. Structural variations causing inherited peripheral neuropathies: a paradigm for understanding genomic organization, chromatin interactions, and gene dysregulation. Mol. Genet. Genom. Med. 6, 422\u2013433 (2018).","journal-title":"Mol. Genet. Genom. Med."},{"key":"1839_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/WCO.0000000000000735","volume":"32","author":"M Laura","year":"2019","unstructured":"Laura, M., Pipis, M., Rossor, A. M. & Reilly, M. M. Charcot-Marie-Tooth disease and related disorders: an evolving landscape. Curr. Opin. Neurol. 32, 641\u2013650 (2019).","journal-title":"Curr. Opin. Neurol."},{"key":"1839_CR4","first-page":"644","volume":"15","author":"M Pipis","year":"2019","unstructured":"Pipis, M., Rossor, A. M., Laura, M. & Reilly, M. M. Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges. Nature reviews. Neurology 15, 644\u2013656 (2019).","journal-title":"Neurology"},{"key":"1839_CR5","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/ene.13079","volume":"23","author":"F Manganelli","year":"2016","unstructured":"Manganelli, F. et al. Nerve conduction velocity in CMT1A: what else can we tell? Eur. J. Neurol. 23, 1566\u20131571 (2016).","journal-title":"Eur. J. Neurol."},{"key":"1839_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2015.05.037","volume":"355","author":"MM Watila","year":"2015","unstructured":"Watila, M. M. & Balarabe, S. A. Molecular and clinical features of inherited neuropathies due to PMP22 duplication. J. Neurological Sci. 355, 18\u201324 (2015).","journal-title":"J. Neurological Sci."},{"key":"1839_CR7","doi-asserted-by":"publisher","unstructured":"Boutary, S. et al. Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future. Transl. Res. J. Lab. Clin. Med. https:\/\/doi.org\/10.1016\/j.trsl.2020.07.006 (2020).","DOI":"10.1016\/j.trsl.2020.07.006"},{"key":"1839_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.nmd.2006.12.008","volume":"17","author":"F Kaya","year":"2007","unstructured":"Kaya, F. et al. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul. Disord. 17, 248\u2013253 (2007).","journal-title":"Neuromuscul. Disord."},{"key":"1839_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0201-x","volume":"9","author":"I Chumakov","year":"2014","unstructured":"Chumakov, I. et al. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J. Rare Dis. 9, 201 (2014).","journal-title":"Orphanet J. Rare Dis."},{"key":"1839_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/mt.2013.250","volume":"22","author":"Z Sahenk","year":"2014","unstructured":"Sahenk, Z. et al. AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy. Mol. Ther. 22, 511\u2013521 (2014).","journal-title":"Mol. Ther."},{"key":"1839_CR11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/nm957","volume":"9","author":"MW Sereda","year":"2003","unstructured":"Sereda, M. W., Meyer zu Horste, G., Suter, U., Uzma, N. & Nave, K. A. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat. Med. 9, 1533\u20131537 (2003).","journal-title":"Nat. Med."},{"key":"1839_CR12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.21307\/ane-2018-018","volume":"78","author":"AJ Kiepura","year":"2018","unstructured":"Kiepura, A. J. & Kocha\u0144ski, A. Charcot\u2011Marie\u2011Tooth type 1 A drug therapies: role of adenylyl cyclase activity and G\u2011protein coupled receptors in disease pathomechanism. Acta Neurobiol. Exp. 78, 198\u2013209 (2018).","journal-title":"Acta Neurobiol. Exp."},{"key":"1839_CR13","doi-asserted-by":"publisher","unstructured":"Dulsat, C. American Academy of Neurology - 69th Annual Meeting (April 22\u201328, 2017 - Boston, Massachusetts, USA). Drugs of Today. 53, 309\u2013319, https:\/\/doi.org\/10.1358\/dot.2017.53.5.2646003 (2017).","DOI":"10.1358\/dot.2017.53.5.2646003"},{"key":"1839_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1172\/JCI96499","volume":"128","author":"HT Zhao","year":"2018","unstructured":"Zhao, H. T. et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J. Clin. Investig. 128, 359\u2013368 (2018).","journal-title":"J. Clin. Investig."},{"key":"1839_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jconrel.2020.02.032","volume":"321","author":"M Caillaud","year":"2020","unstructured":"Caillaud, M., El Madani, M. & Massaad-Massade, L. Small interfering RNA from the lab discovery to patients\u2019 recovery. J. Controlled Release. 321, 616\u2013628 (2020).","journal-title":"J. Controlled Release."},{"key":"1839_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12035-012-8370-x","volume":"47","author":"J Li","year":"2013","unstructured":"Li, J., Parker, B., Martyn, C., Natarajan, C. & Guo, J. The PMP22 gene and its related diseases. Mol. Neurobiol. 47, 673\u2013698 (2013).","journal-title":"Mol. Neurobiol."},{"key":"1839_CR17","doi-asserted-by":"publisher","first-page":"30675","DOI":"10.18632\/oncotarget.5169","volume":"6","author":"S Chira","year":"2015","unstructured":"Chira, S. et al. Progresses towards safe and efficient gene therapy vectors. Oncotarget 6, 30675\u201330703 (2015).","journal-title":"Oncotarget"},{"key":"1839_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","volume":"144","author":"Y Dong","year":"2019","unstructured":"Dong, Y., Siegwart, D. J. & Anderson, D. G. Strategies, design, and chemistry in siRNA delivery systems. Adv. drug Deliv. Rev. 144, 133\u2013147 (2019).","journal-title":"Adv. drug Deliv. Rev."},{"key":"1839_CR19","doi-asserted-by":"publisher","first-page":"E217","DOI":"10.1073\/pnas.1313459110","volume":"111","author":"A Maksimenko","year":"2014","unstructured":"Maksimenko, A. et al. A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc. Natl Acad. Sci. USA 111, E217\u2013E226 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1839_CR20","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/nnano.2014.274","volume":"9","author":"A Gaudin","year":"2014","unstructured":"Gaudin, A. et al. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nat. Nanotechnol. 9, 1054\u20131062 (2014).","journal-title":"Nat. Nanotechnol."},{"key":"1839_CR21","doi-asserted-by":"publisher","first-page":"eaau5148","DOI":"10.1126\/sciadv.aau5148","volume":"5","author":"J Feng","year":"2019","unstructured":"Feng, J. et al. A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine. Sci. Adv. 5, eaau5148 (2019).","journal-title":"Sci. Adv."},{"key":"1839_CR22","doi-asserted-by":"publisher","first-page":"e0125277","DOI":"10.1371\/journal.pone.0125277","volume":"10","author":"G Urbinati","year":"2015","unstructured":"Urbinati, G. et al. Antineoplastic effects of siRNA against TMPRSS2-ERG junction oncogene in prostate cancer. PLoS ONE 10, e0125277 (2015).","journal-title":"PLoS ONE"},{"key":"1839_CR23","doi-asserted-by":"publisher","first-page":"e95964","DOI":"10.1371\/journal.pone.0095964","volume":"9","author":"HM Ali","year":"2014","unstructured":"Ali, H. M. et al. Effects of siRNA on RET\/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations. PloS ONE 9, e95964 (2014).","journal-title":"PloS ONE"},{"key":"1839_CR24","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1021\/jm2000272","volume":"54","author":"M Raouane","year":"2011","unstructured":"Raouane, M. et al. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J. Med. Chem. 54, 4067\u20134076 (2011).","journal-title":"J. Med. Chem."},{"key":"1839_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nbt936","volume":"22","author":"A Reynolds","year":"2004","unstructured":"Reynolds, A. et al. Rational siRNA design for RNA interference. Nat. Biotechnol. 22, 326\u2013330 (2004).","journal-title":"Nat. Biotechnol."},{"key":"1839_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/ana.25480","volume":"85","author":"J Svaren","year":"2019","unstructured":"Svaren, J. et al. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies. Ann. Neurol. 85, 887\u2013898 (2019).","journal-title":"Ann. Neurol."},{"key":"1839_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00019052-200410000-00008","volume":"17","author":"ME Shy","year":"2004","unstructured":"Shy, M. E. Charcot-Marie-Tooth disease: an update. Curr. Opin. Neurol. 17, 579\u2013585 (2004).","journal-title":"Curr. Opin. Neurol."},{"key":"1839_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1515\/cclm-2015-0602","volume":"54","author":"M Gagic","year":"2016","unstructured":"Gagic, M. et al. Analysis of PMP22 duplication and deletion using a panel of six dinucleotide tandem repeats. Clin. Chem. Lab. Med. 54, 773\u2013780 (2016).","journal-title":"Clin. Chem. Lab. Med."},{"key":"1839_CR29","doi-asserted-by":"publisher","first-page":"e1008069","DOI":"10.1371\/journal.pgen.1008069","volume":"15","author":"VG Volpi","year":"2019","unstructured":"Volpi, V. G. et al. Schwann cells ER-associated degradation contributes to myelin maintenance in adult nerves and limits demyelination in CMT1B mice. PLoS Genet. 15, e1008069 (2019).","journal-title":"PLoS Genet."},{"key":"1839_CR30","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1021\/acs.bioconjchem.8b00205","volume":"29","author":"L Massaad-Massade","year":"2018","unstructured":"Massaad-Massade, L. et al. New formulation for the delivery of oligonucleotides using \u201cClickable\u201d siRNA-polyisoprenoid-conjugated nanoparticles: application to cancers harboring fusion oncogenes. Bioconjug. Chem. 29, 1961\u20131972 (2018).","journal-title":"Bioconjug. Chem."},{"key":"1839_CR31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/21691401.2017.1307210","volume":"46","author":"A Singh","year":"2018","unstructured":"Singh, A., Trivedi, P. & Jain, N. K. Advances in siRNA delivery in cancer therapy. Artif. Cells Nanomed. Biotechnol. 46, 274\u2013283 (2018).","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"1839_CR32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/hmg\/10.10.1007","volume":"10","author":"J Perea","year":"2001","unstructured":"Perea, J. et al. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum. Mol. Genet. 10, 1007\u20131018 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"1839_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1046\/j.1469-7580.2002.00039.x","volume":"200","author":"AM Robertson","year":"2002","unstructured":"Robertson, A. M. et al. Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J. Anat. 200, 377\u2013390 (2002).","journal-title":"J. Anat."},{"key":"1839_CR34","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1093\/brain\/awp274","volume":"132","author":"MA Saporta","year":"2009","unstructured":"Saporta, M. A. et al. Shortened internodal length of dermal myelinated nerve fibres in Charcot\u2013Marie-Tooth disease type 1A. Brain 132, 3263\u20133273 (2009).","journal-title":"Brain"},{"key":"1839_CR35","first-page":"206","volume":"65","author":"S Perveen","year":"2015","unstructured":"Perveen, S., Mannan, S., Hussain, A. & Kanwal, S. Charcot-Marie-Tooth type 1A disease from patient to laboratory. J. Pak. Med. Assoc. 65, 206\u2013212 (2015).","journal-title":"J. Pak. Med. Assoc."},{"key":"1839_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0378-1119(01)00793-4","volume":"282","author":"A Robertson","year":"2002","unstructured":"Robertson, A., Perea, J., Tolmachova, T., Thomas, P. K. & Huxley, C. Effects of mouse strain, position of integration and tetracycline analogue on the tetracycline conditional system in transgenic mice. Gene 282, 65\u201374 (2002).","journal-title":"Gene"},{"key":"1839_CR37","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00439-013-1331-2","volume":"132","author":"DN Cooper","year":"2013","unstructured":"Cooper, D. N., Krawczak, M., Polychronakos, C., Tyler-Smith, C. & Kehrer-Sawatzki, H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum. Genet. 132, 1077\u20131130 (2013).","journal-title":"Hum. Genet."},{"key":"1839_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.nbd.2017.01.006","volume":"100","author":"JS Lee","year":"2017","unstructured":"Lee, J. S. et al. Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo. Neurobiol. Dis. 100, 99\u2013107 (2017).","journal-title":"Neurobiol. Dis."},{"key":"1839_CR39","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.biocel.2006.05.007","volume":"38","author":"K Bhatheja","year":"2006","unstructured":"Bhatheja, K. & Field, J. Schwann cells: origins and role in axonal maintenance and regeneration. Int J. Biochem. Cell Biol. 38, 1995\u20131999 (2006).","journal-title":"Int J. Biochem. Cell Biol."},{"key":"1839_CR40","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1523\/JNEUROSCI.5893-10.2011","volume":"31","author":"EA Jones","year":"2011","unstructured":"Jones, E. A. et al. Regulation of the PMP22 gene through an intronic enhancer. J. Neurosci. 31, 4242\u20134250 (2011).","journal-title":"J. Neurosci."},{"key":"1839_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0318-4","volume":"14","author":"A Didonna","year":"2019","unstructured":"Didonna, A. & Opal, P. The role of neurofilament aggregation in neurodegeneration: lessons from rare inherited neurological disorders. Mol. Neurodegeneration 14, 19 (2019).","journal-title":"Mol. Neurodegeneration"},{"key":"1839_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/brain\/awg012","volume":"126","author":"N Hattori","year":"2003","unstructured":"Hattori, N. et al. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain 126, 134\u2013151 (2003).","journal-title":"Brain"},{"key":"1839_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.conb.2014.02.012","volume":"27","author":"CG Geoffroy","year":"2014","unstructured":"Geoffroy, C. G. & Zheng, B. Myelin-associated inhibitors in axonal growth after CNS injury. Curr. Opin. Neurobiol. 27, 31\u201338 (2014).","journal-title":"Curr. Opin. Neurobiol."},{"key":"1839_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ana.24086","volume":"75","author":"J Guo","year":"2014","unstructured":"Guo, J. et al. Abnormal junctions and permeability of myelin in PMP22-deficient nerves. Ann. Neurol. 75, 255\u2013265 (2014).","journal-title":"Ann. Neurol."},{"key":"1839_CR45","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ymthe.2017.05.016","volume":"25","author":"D Sobot","year":"2017","unstructured":"Sobot, D. et al. Circulating lipoproteins: a trojan horse guiding squalenoylated drugs to LDL-accumulating cancer cells. Mol. Ther. 25, 1596\u20131605 (2017).","journal-title":"Mol. Ther."},{"key":"1839_CR46","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1194\/jlr.M057406","volume":"56","author":"S Nagashima","year":"2015","unstructured":"Nagashima, S. et al. Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver. J. Lipid Res. 56, 998\u20131005 (2015).","journal-title":"J. Lipid Res."},{"key":"1839_CR47","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/d41586-018-05867-7","volume":"560","author":"H Ledford","year":"2018","unstructured":"Ledford, H. Gene-silencing technology gets first drug approval after 20-year wait. Nature 560, 291\u2013292 (2018).","journal-title":"Nature"},{"key":"1839_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1839_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","volume":"43","author":"KS Frazier","year":"2015","unstructured":"Frazier, K. S. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective. Toxicol. Pathol. 43, 78\u201389 (2015).","journal-title":"Toxicol. Pathol."},{"key":"1839_CR50","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/nar\/gkaa956","volume":"48","author":"JS Lee","year":"2020","unstructured":"Lee, J. S. et al. Targeted PMP22 TATA-box editing by CRISPR\/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice. Nucleic Acids Res. 48, 130\u2013140 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1839_CR51","doi-asserted-by":"publisher","unstructured":"Gautier, B. et al. Long term AAV2\/9-mediated silencing of PMP22 prevents CMT1A disease in rats and validates skin biomarkers as treatment outcome measure. https:\/\/www.biorxiv.org\/content\/10.1101\/2020.01.29.924605v1. https:\/\/doi.org\/10.1101\/2020.01.29.924605 (2020).","DOI":"10.1101\/2020.01.29.924605"},{"key":"1839_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-017-0418-y","volume":"15","author":"AM Rice","year":"2017","unstructured":"Rice, A. M. & McLysaght, A. Dosage-sensitive genes in evolution and disease. BMC Biol. 15, 78 (2017).","journal-title":"BMC Biol."},{"key":"1839_CR53","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2174\/1389202919666180330153316","volume":"19","author":"V Salpietro","year":"2018","unstructured":"Salpietro, V., Manole, A., Efthymiou, S. & Houlden, H. A review of copy number variants in inherited neuropathies. Curr. Genom. 19, 412\u2013419 (2018).","journal-title":"Curr. Genom."},{"key":"1839_CR54","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1046-2023(02)00023-3","volume":"26","author":"SM Elbashir","year":"2002","unstructured":"Elbashir, S. M., Harborth, J., Weber, K. & Tuschl, T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26, 199\u2013213 (2002).","journal-title":"Methods"},{"key":"1839_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jnr.490320103","volume":"32","author":"JM Boutry","year":"1992","unstructured":"Boutry, J. M. et al. Establishment and characterization of a mouse Schwann cell line which produces myelin in vivo. J. Neurosci. Res. 32, 15\u201326 (1992).","journal-title":"J. Neurosci. Res."},{"key":"1839_CR56","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/ars.2016.6711","volume":"27","author":"M Hichor","year":"2017","unstructured":"Hichor, M. et al. Paraquat induces peripheral myelin disruption and locomotor defects: crosstalk with LXR and Wnt pathways. Antioxid. Redox Signal 27, 168\u2013183 (2017).","journal-title":"Antioxid. Redox Signal"},{"key":"1839_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mus.21253","volume":"40","author":"A Echaniz-Laguna","year":"2009","unstructured":"Echaniz-Laguna, A. et al. Electrophysiological studies in a mouse model of Schwartz-Jampel syndrome demonstrate muscle fiber hyperactivity of peripheral nerve origin. Muscle Nerve 40, 55\u201361 (2009).","journal-title":"Muscle Nerve"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01839-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T14:30:06Z","timestamp":1670077806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01839-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1038\/s42003-021-01839-2","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"10 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B., G.U., D.D., P.C, C.M., and L.M. are inventors of patent EP 18306241.3 and WO 2020\/064749 A1. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}